已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction

医学 阿利罗库单抗 内科学 血管内超声 心肌梗塞 安慰剂 病变 心脏病学 随机对照试验 PCSK9 易损斑块 外科 病理 胆固醇 脂蛋白 低密度脂蛋白受体 替代医学 载脂蛋白A1
作者
Flavio Giuseppe Biccirè,Ryota Kakizaki,Konstantinos C. Koskinas,Yasushi Ueki,Jonas Häner,Hiroki Shibutani,Jacob Lønborg,Ernest Spitzer,Juan F. Iglesias,Tatsuhiko Otsuka,George C.M. Siontis,Stefan Stortecky,Christoph Kaiser,Maria Ambühl,Laura Morf,Anna S. Ondracek,Robert‐Jan van Geuns,David Spirk,Joost Daemen,François Mach
出处
期刊:JAMA Cardiology [American Medical Association]
被引量:13
标识
DOI:10.1001/jamacardio.2024.3200
摘要

Importance Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach). Objective To investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events. Design, Setting, and Participants The PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardial infarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified as segments with plaque burden 40% or greater defined by intravascular ultrasound (IVUS). IVUS, near-infrared spectroscopy, and optical coherence tomography images at baseline and the 52-week follow-up were manually matched by readers blinded to treatment allocation. Data for this study were analyzed from October 2022 to November 2023. Interventions Alirocumab or placebo in addition to high-intensity statin therapy. Main Outcomes and Measures Lesion-level imaging outcome measures, including high-risk plaque characteristics and phenotypes. Results Of the 245 patients in whom lesions were found, 118 were in the alirocumab group (mean [SD] age, 58.2 [10.0] years; 101 [85.6%] male and 17 [14.4%] female) and 127 in the placebo group (mean [SD] age, 57.7 [8.8] years; 104 [81.9%] male and 23 [18.1%] female). Overall, 591 lesions were included: 287 lesions (118 patients, 214 vessels) in the alirocumab group and 304 lesions (127 patients, 239 vessels) in the placebo group. Lesion-level mean change in percent atheroma volume (PAV) was −4.86% with alirocumab vs −2.78% with placebo (difference, −2.02; 95% CI, −3.00 to −1.05; P < .001). At the minimum lumen area (MLA) site, mean change in PAV was −10.14% with alirocumab vs −6.70% with placebo (difference, −3.36; 95% CI, −4.98 to −1.75; P < .001). MLA increased by 0.15 mm 2 with alirocumab and decreased by 0.07 mm 2 with placebo (difference, 0.21; 95% CI, 0.01 to 0.41; P = .04). Among 122 lipid-rich lesions, 34 of 55 (61.8%) in the alirocumab arm and 27 of 67 (41.8%) in the placebo arm showed a less lipid-rich plaque phenotype at follow-up ( P = .03). Among 63 lesions with thin-cap fibroatheroma at baseline, 8 of 26 (30.8%) in the alirocumab arm and 3 of 37 (8.1%) in the placebo arm showed a fibrous/fibrocalcific plaque phenotype at follow-up ( P = .02). Conclusions and Relevance At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes. Trial Registration ClinicalTrials.gov Identifier: NCT03067844
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一直向前发布了新的文献求助10
刚刚
honeylaker发布了新的文献求助10
1秒前
bkagyin应助zsw采纳,获得10
1秒前
1秒前
2秒前
2秒前
斯文败类应助科研通管家采纳,获得10
2秒前
共享精神应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
Owen应助科研通管家采纳,获得10
2秒前
脑洞疼应助科研通管家采纳,获得10
3秒前
CipherSage应助科研通管家采纳,获得10
3秒前
我是老大应助科研通管家采纳,获得10
3秒前
1234发布了新的文献求助10
4秒前
乖猫要努力应助潘善若采纳,获得10
5秒前
41应助潘善若采纳,获得10
5秒前
乖猫要努力应助潘善若采纳,获得10
6秒前
yar应助潘善若采纳,获得10
6秒前
7秒前
涛1118发布了新的文献求助10
8秒前
陶瓷小罐完成签到 ,获得积分10
10秒前
13秒前
胡萝卜发布了新的文献求助10
13秒前
Lion发布了新的文献求助10
14秒前
14秒前
英俊的铭应助小羊采纳,获得10
15秒前
Tuesday完成签到 ,获得积分10
16秒前
VIAI发布了新的文献求助10
17秒前
Ha完成签到,获得积分10
19秒前
beyondjun完成签到,获得积分10
20秒前
深情安青应助温柔烧鹅采纳,获得10
20秒前
21秒前
cbxzhsun发布了新的文献求助10
21秒前
圈圈完成签到 ,获得积分10
22秒前
卖辣条的小浣熊完成签到,获得积分10
22秒前
23秒前
Yuki发布了新的文献求助10
26秒前
研友_VZG7GZ应助VIAI采纳,获得10
27秒前
SUE发布了新的文献求助10
28秒前
Kirito完成签到 ,获得积分0
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208